Skip to content

Safety and Initial Feasibility of Using the Neurolyser for Facet Related Low Back Pain

Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Facet Related Low Back Pain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03321344
Enrollment
10
Registered
2017-10-25
Start date
2017-12-05
Completion date
2020-02-19
Last updated
2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facet Related Low Back Pain

Brief summary

Single arm pilot study to evaluate the safety and initial feasibility of the Neurolyser XR, a new portable high intensity focused ultrasound device, for noninvasive thermal ablation of medial nerve branches of painful lumbar facet joint/s

Detailed description

Study design: Prospective, single arm Timeline: six month enrollment period and 12 months follow-up period. Sites: The study will be conducted at McGill University. Study population: Ten adult patients diagnosed with facet related low back pain. Primary study objective: Safety and efficacy of the Neurolyser XR for the treatment of facet related low back pain. Safety would be evaluated by the incidence and severity of treatment related adverse events Efficacy would be evaluated by the changes in average pain score and Rolland Morris Disability Questionnaire between baseline and 6 months.

Interventions

DEVICEFocused Ultrasound Thermal ablation

Focused Ultrasound Thermal ablation of the Medial Nerve Branch

Sponsors

Focused Ultrasound Foundation
CollaboratorOTHER
FUSMobile Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Single arm, non-randomized

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Adult male and females, legally able and willing to participate in the study and come for follow-up visits 2. Able and willing to fill the study forms and to communicate with investigator 3. Patient with uni or bilateral lumbar facetogenic pain of \> 6 months duration 4. Patients presenting with a) a positive (\>70% pain relief) to a previous L1 to L5 lumbar medial branch block and / or b) with a positive (\>70% pain relief) to a previous lumbar facet thermal RF denervation within the last 6 months) 5. Average pain score of 4 or higher in the last month, (on a scale of 0 to 10)

Exclusion criteria

1. Pregnant or breastfeeding patient 2. Patients younger than 18 or older than 80 years 3. Patients presenting with neurological deficits (including lumbosacral radiculopathy but not radicular pain). 4. History of spine surgery 5. Presence of metal hardware at the lumbosacral spine 6. Lumbar spine pathology that may increase procedural risk and / or influence symptoms and / or generate unrelated adverse event, (per the discretion of the study PI) 7. Patients unable to understand and complete the research questionnaires in English or French 8. Any severe medical condition preventing the patient from safely and effectively being treated in the study or reporting study outcome. 9. Patient with extensive scarring in the skin and tissue overlying the treatment area. 10. Patients enrolled in or planned to be enrolled in another clinical trial during the duration of this research project

Design outcomes

Primary

MeasureTime frameDescription
NRSBase line, 2 days 1, 2 & 4 weeks, 3, 6 & 12 months after procedureReduction in average pain score as measured by a numeric rating scale from 0 (no pain) to 10, worst possible pain
RMDBase line, 1 & 4 weeks, 3, 6 & 12 months after procedureReduction in Rolland Morris Disability Questionnaire score
SafteyBase line, Procedure day, 2 days 1, 2 & 4 weeks, 3, 6 & 12 months after procedureSafety will be measured by the incidence and severity of treatment related adverse events

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026